Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor

Hirofumi Sato, Sei Murakami, Yusuke Horii, Go Nishimura, Ryosuke Iwai, Moritaka Goto and Naoki Takahashi
Molecular Pharmacology August 5, 2022, MOLPHARM-AR-2022-000522; DOI: https://doi.org/10.1124/molpharm.122.000522
Hirofumi Sato
1Sanwa Kagaku Kenkyusho Co., LTD, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sei Murakami
2Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yusuke Horii
2Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Go Nishimura
2Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryosuke Iwai
2Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moritaka Goto
3Pharmaceuticals Research Laboratories, Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Moritaka Goto
  • For correspondence: mo_gotoh@skk-net.com
Naoki Takahashi
2Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

MOLPHARM-AR-2022-000522
DOI 
https://doi.org/10.1124/molpharm.122.000522

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Published online August 5, 2022.

Copyright & Usage 
© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution CC BY License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Author Information

  1. Hirofumi Sato1,
  2. Sei Murakami2,
  3. Yusuke Horii2,
  4. Go Nishimura2,
  5. Ryosuke Iwai2,
  6. Moritaka Goto3,*, and
  7. Naoki Takahashi2
  1. 1Sanwa Kagaku Kenkyusho Co., LTD, Japan
  2. 2Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  3. 3Pharmaceuticals Research Laboratories, Sanwa Kagaku Kenkyusho, Co.,Ltd., Japan
  1. ↵* Corresponding Author:
    Moritaka Goto, Pharmaceuticals Research Laboratories, Sanwa Kagaku Kenkyusho, Co.,Ltd., 363 Shiosaki, Hokusei-cho, Inabe, Mie, N/A, 5110406, Japan. E-mail: mo_gotoh{at}skk-net.com

Statistics from Altmetric.com

Article usage

Article usage: August 2022 to August 2022

AbstractFullPdf
Aug 2022255036

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 102 (3)
Molecular Pharmacology
Vol. 102, Issue 3
1 Sep 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Upacicalcet binds to the amino acid binding site of CaSR

Hirofumi Sato, Sei Murakami, Yusuke Horii, Go Nishimura, Ryosuke Iwai, Moritaka Goto and Naoki Takahashi
Molecular Pharmacology August 5, 2022, MOLPHARM-AR-2022-000522; DOI: https://doi.org/10.1124/molpharm.122.000522

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Upacicalcet binds to the amino acid binding site of CaSR

Hirofumi Sato, Sei Murakami, Yusuke Horii, Go Nishimura, Ryosuke Iwai, Moritaka Goto and Naoki Takahashi
Molecular Pharmacology August 5, 2022, MOLPHARM-AR-2022-000522; DOI: https://doi.org/10.1124/molpharm.122.000522
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Regulation and Mechanisms of ImKTX58 on KV1.3 Channel
  • Human mAb 3F1 Targeting the Functional Epitopes of Siglec-15
  • Effects of Small Molecule Ligands on ACKR3 Receptors
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics